A5006961619- Birth, Development, and Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Gestational Diabetes Research and Management
- Lipoproteins and Cardiovascular Health
- Epigenetics and DNA Methylation
- Obesity, Physical Activity, Diet
- Pregnancy and preeclampsia studies
- Cancer, Lipids, and Metabolism
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
- Lipid metabolism and biosynthesis
- Migration, Identity, and Health
- Diet, Metabolism, and Disease
- Nutrition, Genetics, and Disease
- Diet and metabolism studies
- Social Policies and Family
- Child Nutrition and Feeding Issues
- Liver Disease Diagnosis and Treatment
- Cardiovascular Issues in Pregnancy
- Health and Lifestyle Studies
- Lipid metabolism and disorders
- Food Security and Health in Diverse Populations
- Mitochondrial Function and Pathology
- Education, sociology, and vocational training
McGill University
2018-2025
King Abdulaziz University
2025
Children's Hospital of Eastern Ontario
2025
University of British Columbia
2025
University of Toronto
2025
McMaster Children's Hospital
2025
Hospital for Sick Children
2025
University of Alberta
2025
SickKids Foundation
2025
Society of Interventional Radiology
2022
This scientific statement presents considerations for clinical management regarding the assessment and risk reduction of select pediatric populations at high premature cardiovascular disease, including acquired arteriosclerosis or atherosclerosis. For each topic, evidence accelerated coronary artery disease stroke in childhood adolescence benefit interventions youth will be reviewed. Children adolescents may higher because significant atherosclerotic arteriosclerotic factors, high-risk...
Offspring exposed to gestational diabetes mellitus (GDM) have an increased risk for chronic diseases, and one promising mechanism fetal metabolic programming is epigenetics. Therefore, we postulated that GDM exposure impacts the offspring's methylome used epigenomic approach explore this hypothesis. Placenta cord blood samples were obtained from 44 newborns, including 30 GDM. Women recruited at first trimester of pregnancy followed until delivery. was assessed after a 75-g oral glucose...
OBJECTIVE To verify whether the leptin gene epigenetic (DNA methylation) profile is altered in offspring of mothers with gestational impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS Placental tissues and maternal cord blood samples were obtained from 48 women at term including 23 subjects IGT. Leptin DNA methylation, expression levels, circulating concentration measured using Sequenom EpiTYPER system, quantitative real-time RT-PCR, enzyme-linked immunosorbent assay,...
Growing evidence suggests that epigenetic profile changes occurring during fetal development in response to utero environment variations could be one of the mechanisms involved early determinants adult chronic diseases. In this study, we tested whether maternal glycemic status is associated with adiponectin gene (ADIPOQ) DNA methylation placenta tissue, circulating blood cells, and cord cells. We found lower levels promoter ADIPOQ on side were correlated higher glucose second trimester...
The insulin-like growth factor 2 (IGF2) gene, located within a cluster of imprinted genes on chromosome 11p15, encodes fetal and placental affecting birth weight. DNA methylation variability at the IGF2 gene locus has been previously reported but its consequences development are still mostly unknown in normal pediatric population. We collected one hundred placenta biopsies from 50 women with corresponding maternal cord blood samples measured anthropometric indices, pressure metabolic...
In utero environmental perturbations have been associated with epigenetic changes in the offspring and a lifelong susceptibility to cardiovascular diseases (CVD). DNA methylation at ATP-binding cassette transporter A1 (ABCA1) gene was previously CVD, but whether these marks respond maternal environment is unknown. This study undertaken assess associations between metabolic profile ABCA1 levels placenta cord blood. Placenta blood samples were obtained delivery from 100 women including 26...
Placental lipoprotein lipase (LPL) is crucial for placental lipid transfer. Impaired LPL gene expression and activity were reported in pregnancies complicated by gestational diabetes mellitus (GDM) intra-uterine growth restriction. We hypothesized that DNA methylation altered maternal metabolic status could contribute to fetal programming. The objective of this study was thus assess whether associated with GDM both newborn profiles. Placenta biopsies sampled at delivery from 126 women...
Obesity is a complex, chronic, stigmatized disease whereby abnormal or excess body fat may impair health increase the risk of medical complications, and can reduce quality life shorten lifespan in children families. We developed this guideline to provide evidence-based recommendations on options for managing pediatric obesity that support shared decision-making among living with obesity, their families, care providers. followed Grading Recommendations Assessment, Development Evaluation...
Introduction: Improving access to healthcare for childhood obesity is crucial, especially in contexts where social vulnerability a significant risk factor developing childhood. Little known about whether family grant programs (FGP) help remove systemic and institutional barriers lifestyle therapies children with obesity. Hypothesis: We tested the hypothesis that FGP favors engagement modification program body mass index z-score (BMIz) reduction of overweight or at pediatric management...
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase (LPL) metabolism. The aim present study was to investigate relation between TG-related parameters considered different clinical guidelines used industrialized countries for management lipid disorders (namely fasting plasma TG, high density-lipoprotein cholesterol (HDL-C), non-HDL-C...
Aims: To determine whether placental IGF1R, IGFBP3, INSR and IGF1 DNA methylation mRNA levels were dysregulated when exposed to maternal impaired glucose tolerance (IGT) investigate the epigenetic profile is associated with feto-placental developmental markers. Patients & methods: The IGT diagnosis was made according WHO criteria (IGT: n = 34; normal [NGT]: 106). quantified using bisulfite pyrosequencing qRT-PCR, respectively. Results: IGF1R IGFBP3 lower in placentas compared NGT (-4.3%; p...
Aim: To assess the associations between gestational diabetes mellitus (GDM) and DNA methylation levels at genes related to energy metabolism. Patients & methods: Ten loci were selected from our recent epigenome-wide association study on GDM. quantified by bisulfite pyrosequencing in 80 placenta cord blood samples (20 exposed GDM) an independent birth cohort (Gen3G). Results: We did not replicate However, normoglycemic women, glucose associated with changes LRP1B BRD2 CACNA1D gene blood,...
Evolocumab is a fully human monoclonal antibody inhibitor of PCSK9 approved for lowering low-density lipoprotein cholesterol in adults and pediatric patients with familial hypercholesterolemia (FH). The cognitive safety evolocumab has been established but not yet described patients.To determine the effects on function heterozygous FH.Cognitive was assessed during 24-week, randomized, double-blind, placebo-controlled study (HAUSER-RCT) evaluating efficacy, safety, tolerability 24 weeks...
Abstract Aims PCSK9 inhibition intensively lowers low density lipoprotein cholesterol and is well tolerated in adults paediatric patients with familial hypercholesterolaemia (FH). HAUSER-RCT showed that 24 weeks of treatment evolocumab did not affect cognitive function. This study determined the effects 80 additional on function heterozygous FH. Methods results HAUSER-OLE was an 80-week open-label extension HAUSER-RCT, a randomized, double-blind, 24-week trial evaluating efficacy safety...